Featured Research

from universities, journals, and other organizations

Novel Treatment Target For Deadly Brain Tumors Identified

Date:
November 1, 2005
Source:
Wake Forest University Baptist Medical Center
Summary:
Researchers at Wake Forest University Baptist Medical Center have identified a second promising treatment target for glioblastoma multiforme, one of the most deadly types of brain tumors. The research results are reported in the October issue of Molecular Cancer Research.

Researchers at Wake Forest University Baptist Medical Center have identified a second promising treatment target for glioblastoma multiforme, one of the most deadly types of brain tumors. The research results are reported in the October issue of Molecular Cancer Research.

"We've found that a particular protein may play a major role in the progression of these tumors, suggesting an attractive new treatment approach," said Waldemar Debinski, M.D., Ph.D., director of the Brain Tumor Center of Excellence at Wake Forest University Baptist Medical Center.

This was the first study to investigate the presence and significance of a protein called EphA2 in brain cancer cells. This protein, which is found in cell membranes, allows normal cells to communicate with their environment and each other. In its normal active state, the protein seems to inhibit abnormal cell growth and division.

Debinski and colleagues demonstrated that glioblastoma cells have significantly increased levels of the protein EphA2 compared to normal cells -- but it is in an inactive form. They believe that this inactive form of EphA2 aids in the survival and spread of cancer cells.

To test their hypothesis, they treated glioblastoma cells with ephrinA1, a naturally occurring molecule that binds to EphA2 and activates it. They had already demonstrated that ephrinA1 is present at much lower levels in cells and tumors with increased levels of inactive EphA2.

"We observed that cells treated with ephrinA1 slowed down their growth and were less likely to exhibit invasive properties," said Debinski.

The researchers believe that developing medication to change levels of EphA2 and ephrinA1 offers new promise for successfully treating glioblastoma multiforme, which is the most common form of brain tumor and the least curable of all human cancers. The majority of the 17,500 brain tumors diagnosed each year in the United States are glioblastomas. Patients have a median survival time of nine to 12 months and a five-year survival rate of 1 to 5 percent.

"EphA2 represents a novel target for the development of molecular therapeutics for the imaging and treatment of patients with glioblastoma," said Debinski. "New therapies are clearly needed because, despite the standard treatment of surgically removing the tumor and treating the patient with chemotherapy and radiation, survival has increased only slightly over the past 30 years."

Debinski has already developed one treatment for glioblastoma, based on his discovery that the tumor's cells have a particular type of receptor for interleukin 13 (IL 13), a naturally occurring protein that regulates the immune system in the body. Normal cells do not have these same receptors. Debinski developed a drug that combines a form of IL-13 with a toxin that kills cancer cells. By targeting the therapy to these receptors, the drug finds and kills the cancer cells. The first generation of the drug is being tested in advanced clinical trials worldwide.

Both of Debinki's projects focus on the identification of "molecular markers," or molecules that are found in high levels on tumor cells but are nearly absent on normal cells. This makes them attractive for such treatment approaches as targeted drug delivery.

EphA2 may also show promise for treating other types of cancer. It has been shown to be present at high levels in several other tumors, such as pancreas, colon and breast. And recently other researchers have shown that EphA2 is a potential target for a glioblastoma vaccine that could potentially prevent recurrences of the tumors.

Debinski's results were preliminarily reported at the World Federation of NeuroOncology meeting and the European Association for Neuro-Oncology meeting, both in Edinburgh, Scotland, in May. Jill Wykosky, B.S., and Denise Gibo, B.S., from Debinski's laboratory, conducted this work, and Constance Stanton, M.D., from the Department of Pathology, collaborated.



Story Source:

The above story is based on materials provided by Wake Forest University Baptist Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Wake Forest University Baptist Medical Center. "Novel Treatment Target For Deadly Brain Tumors Identified." ScienceDaily. ScienceDaily, 1 November 2005. <www.sciencedaily.com/releases/2005/10/051031075514.htm>.
Wake Forest University Baptist Medical Center. (2005, November 1). Novel Treatment Target For Deadly Brain Tumors Identified. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2005/10/051031075514.htm
Wake Forest University Baptist Medical Center. "Novel Treatment Target For Deadly Brain Tumors Identified." ScienceDaily. www.sciencedaily.com/releases/2005/10/051031075514.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
US to Track Everyone Coming from Ebola Nations

US to Track Everyone Coming from Ebola Nations

AP (Oct. 22, 2014) Stepping up their vigilance against Ebola, federal authorities said Wednesday that everyone traveling into the US from Ebola-stricken nations will be monitored for symptoms for 21 days. (Oct. 22) Video provided by AP
Powered by NewsLook.com
Doctors Help Paralysed Man Walk Again, Patient in Disbelief

Doctors Help Paralysed Man Walk Again, Patient in Disbelief

AFP (Oct. 22, 2014) Polish doctors describe how they helped a paralysed man walk again, with the patient in disbelief at the return of sensation to his legs. Duration: 1:04 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins